bioRxiv Science⌕ Search

Biology subjects

Gibb, J. I.

Publications and source records attributed to Gibb, J. I..

4 recordsLinked to original sources

CONTROLLING COCKROACH POPULATIONS IN HUMAN AND ANIMAL HABITATIONS BY REDUCING FOOD AVAILABILITY

BackgroundCockroaches, carriers of pathogenic organisms that cause human and animal disease, typically have access to human or pet food in bowls, allowing cockroaches to expand their colonies and infestations. HypothesisWe hypothesized that existing anti-ant technology could be converted to anti-cockroach technology by simple design changes. MethodsA base of various heights was affixed to the bottom of an anti-ant bowl to increase the distance of the anti-ant shield from the native height "x" to the hypothesized cockroach-resistant height "z". The effects of z =0, 12.7, 15.9, 19.1, 25.4, 44.5, and 57.2 mm were studied. 118.3 cc (4 oz) of dry cat food was used as cockroach bait. The modified anti-ant bowls were placed in a high-intensity cockroach environment during summer nights where the temperatures varied between 23.9-29.4 degrees Celsius for 3 hours and then cockroach counts were performed. Ten runs at each height z were performed. ResultsMean numbers of infesting cockroaches {+/-} SD at each height z were 21.3{+/-}2.9 at 0 mm, 22.0{+/-}2.9 at 12.7 mm, 11.2{+/-}2.6 at 15.9 mm, 0.9{+/-}0.8 at 19.1mm, 0.4{+/-}0.5 at 25.4 mm, 0{+/-}0 at 44.5 mm, and 0{+/-}0 at 57.2 mm (p<0.001 with z[&ge;]15.9 mm for all). Cockroach numbers began declining when z = 15.9 mm and declined to only large cockroaches at z = 25.4 mm. The cockroaches that were able to overcome the z =25.4 mm were the larger American cockroaches that can exceed 76.2 mm (3 inch) in length. However, at z = 44.5 mm and 57.2 mm no cockroaches penetrated the modified bowl. ConclusionsTo defeat the majority of species of cockroaches the anti-insect shield should be at a height of at least 25.4 mm and to defeat the larger American cockroaches preferably greater than 25.4 mm with 44.5 mm and 57.2 mm defeating all tested cockroaches

animal behavior and cognition↗

Glenohumeral Injection Using Anatomic Landmark Versus Sonographic Needle Guidance

ObjectiveWe hypothesized ultrasound (US) guidance improves outcomes of corticosteroid injection of the painful shoulder.\n\nMethods30 patients with symptomatic shoulders due to osteoarthritis were randomized to glenohumeral injection with 3 milliliters of 1% lidocaine and 60 mg of triamcinolone acetonide using the anterior approach with 1) conventional anatomic landmark palpation-guidance or 2) US-guidance. Injection pain (visual analogue pain scale (VAS)), pain at outcome (2 weeks and 6 months), therapeutic duration, time-to-next-injection, and costs were determined.\n\nResultsInjection pain was less with US (VAS: 0.3{+/-}0.6 cm) vs. landmark-guidance (VAS: 1.4{+/-}2.4 cm, 95% CI of difference: 0.5<1.1<1.7, p=0.05). Pain scores were similar at 2 weeks: US: 2.2{+/-}2.4 cm; Landmark: 1.8{+/-}2.7 cm, 95% CI of difference: -2.2<-0.4<1.4, p=0.66 and 6 months: US: 5.8{+/-}2.8 cm; Landmark: 6.4{+/-}2.9 cm, 95% CI of difference: -0.4<0.6< 1.1, p =0.71. Therapeutic duration (US: 3.9{+/-}1.5 months; Landmark: 3.0{+/-}1.2 months, 95% CI of difference: - 1.4 <-0.9<-0.4, p=0.045) and time-to-next-injection (US: 8.1{+/-}3.5 months; Landmark: 5.7{+/-}2.9 months, 95% CI of difference: -3.6<-2.4<-1.3, p=0.025) were longer, and fewer injections per year (29% less) were required: US: 1.5{+/-}0.2 injections/year; Landmark: 2.1{+/-}0.2 injections/year (p<0.037; 95% CI of difference -0.9<-0.6<-0.3). However, cost/patient/year was modestly greater with US (US: $318{+/-}89, Landmark: $301{+/-}67; p=0.28).\n\nConclusionAnatomic landmark guidance in the short-term is equally effective as US for injection of the osteoarthritic shoulder and modestly less costly, however, US may reduce the need for repetitive injections by prolonging the therapeutic effect and thus time to next injection.\n\nIRB StatementThis project was in compliance with the Helsinki Declaration, was approved by the Institutional Review Board (IRB) as ultrasound subset of a syringe safety trial (Human Research Review Committee approval 04-347), and was registered at ClinicalTrials.gov (Clinical Trial Identifier NCT00651625). The subjects gave informed consent to participate prior to all studies and interventions. Patient confidentiality was protected according to the U.S. Health Insurance Portability and Accountability Act (HIPAA) and all data was de-identified.

clinical trials↗

Prescription Opioid Analgesic Use and Mortality in Systemic Lupus Erythematosus

ObjectivesThis research investigated the prevalence of opioid analgesic use in patients with systemic lupus erythematosus (SLE).\n\nMethodsThis 5-year prospective cohort study of 275 SLE patients focused on prescription opioid use and 5-year outcome. Associations were determined with univariable regression analysis and then multivariable models were created to determine independent effects on dependent variables\n\nResultsPrescription opioid use was common in SLE with 24% using opioid analgesics chronically and 76% not using opioids. Opioid users had a higher rate of tobacco use (p<0.01), cocaine use (p<0.002), mean pain scores (p<0.001), disease activity (SLEDAI-2K) (p<0.001), disease damage (SLICC/ACRDI) (p<0.001), non-adherence to medical therapy (p<0.01), and total deaths at 5 years (opioids: 48.0%, no opioids 19.0%, p<0.001). Logistic regression analysis predicting death revealed opioid use (hazard ratio 2.6, p<0.001) and SLEDAI-2K (1.1, p<0.001) respectively; and opioid use (hazard ratio 2.5, p<0.002), SLEDAI-2K (hazard ratio 1.1, p<0.001), and non-adherence (hazard ratio 1.6, p=0.11), respectively. Multivariable Cox Model analysis estimating probability of death with covariates: opioid use (hazard ratio 2.6, p<0.001) and SLEDAI-2K (hazard ratio 1.1, p<0.001); opioid use (hazard ratios 3.0, p<0.001), and cocaine use (hazard ratio 3.2, p<0.001). The Kaplan-Meir survival analysis revealed a significantly higher probability of death for SLE patients using opioid analgesics.\n\nConclusionsPrescription opioid analgesic use is common in SLE and is associated with markedly increased mortality. Preferably, non-opioid approaches to treat chronic pain should be used in SLE patients.\n\nClinical trial registration numberThis was not a clinical trial.\n\nKEY MESSAGES1. Chronic opioid analgesic use is common in SLE (24%).\n\n2. Opioid use is associated with greater disease severity, tobacco use, non-adherence, and increased mortality.\n\n3. Opioids should be used cautiously in SLE; alternative non-opioid management of pain is recommended.\n\nACKNOWLEDGMENTS AND FUNDING INFORMATIONThis work was supported by US National Institutes of Health research grants to Dr. Sibbitt (R01 NS035708) and to the Clinical and Translational Research Center (UL1TR001449).

epidemiology↗

Medical Nonadherence, Cannabis Use, and Renal Outcome in Systemic Lupus Erythematosis

Background/ObjectiveNon-adherence to recommended medical therapy has been associated with poorer outcomes in systemic lupus erythematosus (SLE). The present research investigated the association of medical non-adherence and cannabis use on renal outcomes of SLE.\n\nMethodsThis was a prospective 5-year longitudinal outcome study of 276 female SLE patients 30.4% who chronically used medical cannabis and 69.5% who did not. Outcomes were determined at 5 years after enrollment in the study.\n\nResultsCannabis use in SLE patients was associated with an increased prevalence of neuropsychiatric SLE (p<0.05), opioid analgesic use (p<0.01), cigarette smoking (p<0.001), and non-adherence to the medical regimen (non-cannabis: 3% non-adherence vs. cannabis use: 95% non-adherence, p<0.001). Within the 5-year period, the cannabis group demonstrated a 53% increase in mortality (p=0.12) and 127% increase in end-stage renal disease requiring dialysis (p<0.001). With logistic regression analysis adjusting for SLE disease activity (SLEDAI-2K), cannabis use was an independent predictor of end-stage renal disease: Odds ratio 2.65 (CI 1.32 - 5.32, p<0.01). Adjusting for SLE disease damage (SLICC/ACR-DI), cannabis use remained an independent predictor of end-stage renal disease: Odds ratio 2.0 (CI 1.26 - 6.23, p<0.01). With multivariable analysis adjusting for non-adherence, the effect of cannabis on end-stage renal disease could be largely attributed to an increase in non-adherence to medical therapy.\n\nConclusionsNon-adherence to recommended therapy and medical cannabis use are associated with a significant increase in the development of end-stage renal disease in SLE.

epidemiology↗